Arwa Mohamed Hosni, MD
Pulmonary Disease · Ypsilanti, MINPI 1912181496
Payments from drug & device makers
Across 38 payments — averaging $386.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Pulmonx Corporation$4K
- Inspire Medical Systems, Inc.$2K
What the payments were for
- Travel & lodging$6,93547%
- Food & beverage$2,26215%
- Education$5,50037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 24 | $9,547 |
| Pulmonx Corporation | 12 | $3,617 |
| Inspire Medical Systems, Inc. | 2 | $1,532 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,696 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 46 | $534,042 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 270 | $258,374 |
| TezspireTezepelumab-Ekko | 13 | $57,378 |
| NucalaMepolizumab | 14 | $51,775 |
| Spiriva RespimatTiotropium Bromide | 46 | $34,760 |
| XolairOmalizumab | 18 | $30,116 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $29,385 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 77 | $20,663 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 88 | $20,632 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $20,201 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $19,945 |
| Tiotropium Bromide | 35 | $18,904 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $17,137 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $16,567 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $15,968 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Ypsilanti
- Thomas GravelynYpsilanti$104K
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
- Oscar Parodi Ortiz de VillateWarren$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.